文献速递白血病造血干细胞移植与细胞治疗

急性白血病造血干细胞移植后预防复发:移植后微小残留病(MRD)监测与MRD导向干预的作用

Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention.
PubMed 文献 · Br J Haematol · 2017-05-23

急性白血病(AL)异基因造血干细胞移植(allo-HSCT)后,复发是治疗失败的主要原因。移植后微小残留病(MRD)监测可进行风险分层并识别复发风险较高的AL患者,MRD评估主要采用多参数流式细胞术检测白血病相关免疫表型,以及基于聚合酶链反应(PCR)评估白血病相关基因表达水平。多种MRD导向干预已显示可降低复发风险且治疗相关毒性可接受,供者淋巴细胞输注(DLI)是MRD阳性患者最重要的干预措施。

要点

  • 移植后MRD监测可对AL患者进行风险分层,识别复发风险较高者。
  • MRD评估主要用多参数流式细胞术检测白血病相关免疫表型,及PCR评估白血病相关基因表达。
  • DLI是MRD阳性患者最重要的干预措施,改良策略可进一步提高其安全性和疗效。

核心结论

  • 移植后MRD监测可对急性白血病患者进行风险分层并识别复发风险较高者,多种MRD导向干预已显示能降低复发风险且治疗相关毒性可接受。

研究设计与样本

  • 本文为综述,总结allo-HSCT后AL患者MRD监测与MRD导向干预这一快速发展的领域。

主要发现

  • MRD评估主要采用多参数流式细胞术测定白血病相关免疫表型,以及基于PCR评估白血病相关基因表达水平(特异性交互基因重排及其他突变类型)。
  • 二代测序和数字PCR可能进一步丰富现有MRD检测。
  • DLI是MRD阳性患者最重要的干预措施,粒细胞集落刺激因子动员的外周血细胞后短期免疫抑制及递增剂量方案等改良策略进一步提高DLI的安全性和疗效。
  • 干扰素治疗、靶向药物及低甲基化药物也被引入作为MRD导向干预。

临床怎么用

  • 作者在综述中围绕是否及哪些患者可根据MRD从抢先干预中获益这一问题,总结了allo-HSCT后AL患者的MRD监测与MRD导向干预。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapse is the main cause of treatment failure after allogeneic haematopoietic stem cell transplantation (allo-HSCT) for acute leukaemia (AL). Post-transplantation minimal residual disease (MRD) monitoring enables risk stratification and identifies AL patients at higher risk of relapse. MRD assessment primarily involves the determination of leukaemia-associated immunophenotypic patterns using multiparameter flow cytometry, and the polymerase chain reaction (PCR)-based evaluation of expression levels of leukaemia-related genes (specific reciprocal gene rearrangements and other mutation types). In addition, next generation sequencing and digital PCR may further enrich current MRD detection. Several MRD-directed interventions have demonstrated the ability to reduce the risk of relapse with acceptable treatment-related toxicities. Donor lymphocyte infusion (DLI) is the most important intervention for MRD-positive patients, while several modified strategies, such as granulocyte colony-stimulating factor-mobilized peripheral blood cells followed by short term immune suppression and escalating dose regimen, further improve the safety and efficacy of DLI. Interferon therapy, targeted drugs, and hypomethylating agents have also been introduced for MRD-directed interventions. Referring to the issues of whether and who would benefit from pre-emptive intervention according to MRD, in this review, we summarized this rapidly evolving area of MRD monitoring and MRD-directed interventions in AL patients after allo-HSCT.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Mo XD, Lv M, Huang XJ, et al. Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention. Br J Haematol. 2017. PMID: 28542711. doi:10.1111/bjh.14778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。